

Novel Versatile Fullerene Synthons[†]

Konstantinos Kordatos, Tatiana Da Ros, Susanna Bosi, Ester Vázquez, Massimo Bergamin, Claudia Cusan, Federica Pellarini, Véronique Tomberli, Benedetta Baiti, Davide Pantarotto, Vasilios Georgakilas, Giampiero Spalluto, and Maurizio Prato*

Dipartimento di Scienze Farmaceutiche, Università di Trieste, Piazzale Europa 1, 34127 Trieste, Italy

prato@univ.trieste.it

Received March 2, 2001

We report the synthesis of three novel, versatile fullerene intermediates whose main feature is the presence of an amino end group. Simple condensation reactions of these intermediates under standard conditions produce new derivatives that are useful for applications in materials science and medicinal chemistry.

Introduction

The chemical modification of fullerenes has continued unabated in the past few years,^{1,2} mainly devoted to the production of stable derivatives that are useful for applications in materials science^{3,4} and medicinal chemistry.^{5,6} C₆₀ and its derivatives, in fact, have been considered for use in research fields currently of the highest technological interest because of several properties exhibited by this new allotropic form of carbon. It is the combination of these properties that makes these compounds so special, e.g., photophysical⁷ and electrochemical⁸ properties.^{9,10} In the ground state, most fullerene derivatives possess strong absorptions in the UV region and weaker but significant absorptions over most of the visible region, where the singlet and the triplet excited states also absorb.^{7,11} In addition, C₆₀ and its derivatives are excellent three-dimensional electron acceptors and possess a low reorganization energy.^{11–13} These characteristics offer the advantage of preparing fullerene-based dyads or triads in which photoinduced charge transfer is accelerated and charge recombination is decelerated.^{7,10,12,14,15} Additionally, heterogeneous mixtures of C₆₀ with a number of conjugated polymers have led to the production of plastic solar cells, which have just started to be developed.^{16–19} C₆₀ is also a promising nonlinear optical material, as shown in optical-limiting experi-

ments, with performances comparable to those of other classes of useful materials.²⁰

On the other hand, there have been many suggestions for the use of these molecules in medicinal chemistry.^{5,6,21} The introduction of polar groups onto the sphere of C₆₀ gives rise to an increased solubility of the fullerene derivatives in polar solvents, a condition necessary for performing biological tests.

In most cases, a specific functionalization type of C₆₀ is required, using purpose-tailored approaches. In this paper, we demonstrate how a common intermediate can be conveniently used to reach different objectives. In particular, we focus on the synthesis of the amino-functionalized synthons (**A**) (Chart 1) and their conversion into the useful derivatives (**B–E**), containing the correct functionalities for the desired applications. The presence of a silicon alkoxide group on C₆₀ (**B**) guarantees the homogeneous grafting of the resulting fullerene derivatives to glassy matrixes using sol–gel processing. In fact, we have recently shown that the nonlinear optical properties of C₆₀ are retained after incorporation in thin glassy films.^{22,23} To increase the optical-limiting performance while avoiding the formation of clusters, the functionalization of C₆₀ with silicon alkoxide end groups was necessary.

A methodology for the preparation of well-ordered photoactive thin films is the self-assembly of suitably functionalized derivatives. By this method, the corresponding molecules of interest chemically bind onto

[†] In memory of our former lab mate, Sonia Merlo (1972–2000), whose young and exuberant life was interrupted so early and abruptly.

(1) *Fullerenes and Related Structures*, Hirsch, A., Ed.; Springer: Berlin, 1999; Vol. 199.

(2) Diederich, F.; Thilgen, C. *Science* **1996**, *271*, 317–323.

(3) Prato, M. *J. Mater. Chem.* **1997**, *7*, 1097–1109.

(4) Prato, M. *Top. Curr. Chem.* **1999**, *199*, 173–188.

(5) Da Ros, T.; Prato, M. *Chem. Commun.* **1999**, 663–669.

(6) Wilson, S. R. In *The Fullerene Handbook*; Kadish, K., Ruoff, R., Eds.; Wiley: New York, 2000; pp 437–465.

(7) Guldi, D. M. *Chem. Commun.* **2000**, 321–327.

(8) Echegoyen, L.; Echegoyen, L. E. *Acc. Chem. Res.* **1998**, *31*, 593–601.

(9) Martín, N.; Segura, J.; Seoane, C. *J. Mater. Chem.* **1997**, *7*, 1661–1676.

(10) Martín, N.; Sánchez, L.; Illescas, B.; Pérez, I. *Chem. Rev.* **1998**, *98*, 2527–2547.

(11) Guldi, D. M.; Prato, M. *Acc. Chem. Res.* **2000**, *33*, 695–703.

(12) Imahori, H.; Sakata, Y. *Eur. J. Org. Chem.* **1999**, 5, 2445–2457.

(13) Imahori, H.; Hagiwara, K.; Aoki, M.; Akiyama, T.; Taniguchi, S.; Okada, T.; Shirakawa, M.; Sakata, Y. *Chem. Phys. Lett.* **1996**, *263*, 545–550.

(14) Imahori, H.; Sakata, Y. *Adv. Mater.* **1997**, *9*, 537–546.

(15) Imahori, H.; Tamaki, K.; Yamada, H.; Yamada, K.; Sakata, Y.; Nishimura, Y.; Yamazaki, I.; Fujitsuka, M.; Ito, O. *Carbon* **2000**, *38*, 1599–1605.

(16) Sariciftci, N. S.; Smilowitz, L.; Heeger, A. J.; Wudl, F. *Science* **1992**, *258*, 1474–1476.

(17) Sariciftci, N. *Curr. Opin. Solid State Mater. Sci.* **1999**, *4*, 373–378.

(18) Brabec, C.; Sariciftci, N.; Hummelen, J. *Adv. Funct. Mater.* **2001**, *11*, 15–26.


(19) Shaheen, S. E.; Brabec, C. J.; Sariciftci, N. S.; Padinger, F.; Fromherz, T.; Hummelen, J. C. *Appl. Phys. Lett.* **2001**, *78*, 841–843.

(20) Tutt, L. W.; Kost, A. *Nature* **1992**, *356*, 225–226.

(21) Jensen, A. W.; Wilson, S. R.; Schuster, D. I. *Bioorg. Med. Chem.* **1996**, *4*, 767–779.

(22) Signorini, R.; Zerbetto, M.; Meneghetti, M.; Bozio, R.; Maggini, M.; De Faveri, C.; Prato, M.; Scorrano, G. *Chem. Commun.* **1996**, 1891–1892.


(23) Maggini, M.; Faveri, C. D.; Scorrano, G.; Prato, M.; Brusatin, G.; Guglielmi, M.; Meneghetti, M.; Signorini, R.; Bozio, R. *Chem. Eur. J.* **1999**, *5*, 2501–2510.



surfaces forming highly organized monolayers. The formation of self-assembled monolayers (SAM) of C₆₀-based dyads and triads containing a thiol group onto gold electrodes has been successfully reported, producing photoactive elements with high quantum yields.^{24–26} The fabrication of solid-contact ion-selective electrodes using SAM of a redox-active C₆₀-attached alkanethiol compound was also recently reported.²⁷ In this context, a thiol-functionalized fullerene derivative (**C**) can be prepared through the condensation of **A** with the appropriate carboxylic acid containing a thiol-protected group.

A major problem for the development of fullerenes in biology is represented by the insolubility of C₆₀ in biological fluids. For this reason, one of the aims of the chemical modification of fullerene is the introduction of polar chains.^{28,29} Positively charged fullerene derivatives (**D**) give enhanced polarity and high affinity for biological membranes.³⁰ They are relatively easily prepared through the methylation of **A**.

A particularly interesting biological application of fullerene derivatives is related to the DNA photocleavage



ability of C₆₀ derivatives.^{31,32} In principle, the action can be rendered more specific if conjugation with DNA minor-groove binders, such as trimethoxyindole,³³ is achieved.³⁴ In fact, it is well-known that this unit, in a manner characteristic of a class of natural antibiotics named duocarmycins, confers high affinity and selectivity for the minor groove in AT-rich sequences of DNA.³⁵ Condensation of the common intermediate (**A**) with heterocyclic carboxylic acids leads to the novel DNA probes (**E**).

Results and Discussion

The general synthetic strategy should allow the easy preparation of a common intermediate, characterized by the presence of a reactive group, which should permit functionalization by general methods. Given the many easy ways to perform an amide linkage under standard peptide chemistry, we focused on the synthesis of an amino-functionalized fullerene as an intermediate. This can be achieved by means of 1,3-dipolar cycloaddition of azomethine ylides to C₆₀^{36,37} using different commercially available or readily synthesized aldehydes and N-(ω -amino)-functionalized amino acids prepared through the alkylation of monoprotected diamines. For this purpose and for obtaining spacers of different lengths, we have synthesized the α -amino acids **1a–c** in three synthetic steps (Scheme 1). The Boc-monoprotected diamines **3a–c**, prepared by starting from diamines **2a–c** and di-*tert*-butyl dicarbonate in dioxane, were allowed to react with benzyl bromoacetate and triethylamine in dioxane at 0 °C to give the corresponding glycine benzyl esters **4a–c**. Hydrogenolysis of **4a–c** in the presence of catalytic Pd/C in methanol afforded the corresponding α -amino acids **1a–c**.

Thus, α -amino acids **1a–c** were allowed to react with formaldehyde **5**, ferrocene carboxaldehyde (Fc-CHO) **6**, and triethylene glycol aldehyde **7** (CH₃OCH₂CH₂OCH₂CH₂OCH₂CHO = mTEG-CHO)³⁸ and C₆₀ in refluxing toluene to form a variety of N-Boc-protected amino

(24) Hirayama, D.; Yamashiro, T.; Takimiya, K.; Aso, Y.; Otsubo, T.; Norieda, H.; Imahori, H.; Sakata, Y. *Chem. Lett.* **2000**, 570–571.
 (25) Imahori, H.; Azuma, T.; Ozawa, S.; Yamada, H.; Ushida, K.; Ajavakom, A.; Norieda, H.; Sakata, Y. *Chem. Commun.* **1999**, 557–558.

(26) Imahori, H.; Yamada, H.; Nishimura, Y.; Yamazaki, I.; Sakata, Y. *J. Phys. Chem. B* **2000**, *104*, 2099–2108.

(27) Fibbioli, M.; Bandyopadhyay, K.; Liu, S. G.; Echegoyen, L.; Enger, O.; Diederich, F.; Bühlmann, P.; Pretsch, E. *Chem. Commun.* **2000**, 339–340.

(28) Sijbesma, R.; Srdanov, G.; Wudl, F.; Castoro, J. A.; Wilkins, C.; Friedman, S. H.; DeCamp, D. L.; Kenyon, G. L. *J. Am. Chem. Soc.* **1993**, *115*, 6510–6512.

(29) Richardson, C. F.; Schuster, D. I.; Wilson, S. R. *Org. Lett.* **2000**, *2*, 1011–1014.

(30) Bosi, S.; Da Ros, T.; Castellano, S.; Banfi, E.; Prato, M. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1043–1045.

(31) Tokuyama, H.; Yamago, S.; Nakamura, E.; Shiraki, T.; Sugiura, Y. *J. Am. Chem. Soc.* **1993**, *115*, 7918–7919.

(32) Boutorine, A.; Tokuyama, H.; Takasugi, M.; Isobe, H.; Nakamura, E.; Hélène, C. *Angew. Chem., Int. Ed. Engl.* **1994**, *33*, 2462–2465.

(33) Boger, D.; Ishizaki, T.; Zarrinmayeh, H.; Kito, P.; Suntornwat, O. *J. Org. Chem.* **1990**, *55*, 4499–4502.



(34) Bergamin, M.; Da Ros, T.; Spalluto, G.; Boutorine, A.; Prato, M. *Chem. Commun.* **2001**, 17–18.

(35) Boger, D. L.; Johnson, D. S. *Angew. Chem., Int. Ed. Engl.* **1996**, *35*, 1438–1474.

(36) Maggini, M.; Scorrano, G.; Prato, M. *J. Am. Chem. Soc.* **1993**, *115*, 9798–9799.


(37) Prato, M.; Maggini, M. *Acc. Chem. Res.* **1998**, *31*, 519–526.

Scheme 2



- a, X = -CH₂CH₂-, R = -H
b, X = -CH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -H
c, X = -CH₂CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -H
d, X = -CH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -Fc
e, X = -CH₂CH₂-, R = -CH₂OCH₂CH₂OCH₂CH₂OCH₃
f, X = -CH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -CH₂OCH₂CH₂OCH₂CH₂OCH₃

Scheme 3




fulleropyrrolidines **8a–f** in good yields. Removal of the *N*-*tert*-butoxycarbonyl protecting group, using trifluoroacetic acid in CH₂Cl₂, gave the corresponding ammonium-fulleropyrrolidine salts **9a–e** that can react readily with many different compounds.

For example, we have first utilized the newly synthesized intermediates **9b** and **9d** to introduce a silicon alkoxide functionality onto C₆₀ in a simple reaction step. Ammonium-fulleropyrrolidine salts **9b** and **9d** reacted readily with 3-(triethoxysilyl)propyl isocyanate in CH₂-Cl₂ in the presence of triethylamine to afford the desired triethoxysilyl fulleropyrrolidines **10** and **11** in high yields (Scheme 3). These substrates are ideally suited for incorporation in sol-gel glasses for optical-limiting purposes.²³


Using compound **9b**, we could easily introduce a chain onto C₆₀ containing a protected thiol group for SAM purposes through condensation with 12-acetylsulfanyl-dodecanoic acid in the presence of EDC and HOBt (Scheme 4), thus affording fulleropyrrolidine **12** in a high yield. An efficient entry into the deprotection of thiol esters in fullerene derivatives has been recently described²⁷ and shows that, in principle, compound **12** may be conveniently used as a thiol precursor for thin-film preparation.

Positively charged fullerene derivatives have shown excellent growth inhibition properties against a number of microorganisms, in particular, resistant strains of

Scheme 4




Scheme 5



- 13, 16, X = -CH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -H
14, 17, X = -CH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -CH₂OCH₂CH₂OCH₂CH₂OCH₃
15, 18, X = -CH₂CH₂CH₂OCH₂CH₂OCH₂CH₂OCH₂CH₂-, R = -H

Scheme 6



- 19, X = -NH-, R' = -OCH₃
20, X = -NH-, R' = -H
21, X = -O-, R' = -H
22, R = -H, X = -NH-, R' = -OCH₃
23, R = -CH₂OCH₂CH₂OCH₂CH₂OCH₃, X = -NH-, R' = -OCH₃
24, R = -CH₂OCH₂CH₂OCH₂CH₂OCH₃, X = -NH-, R' = -H
25, R = -H, X = -O-, R' = -H

Mycobacteria.³⁰ Compounds **8b**, **8c**, and **8f** were easily methylated using methyl iodide in chloroform at 80 °C, and the resulting salts were deprotected using HCl gas in a methanol solution, affording derivatives **16–18** (Scheme 5).

The presence of two positive charges, along with the increasing number of oxygen atoms, enhanced the solubility in polar solvents, including water.

Compounds **9a** and **9e** could be condensed with the appropriate carboxylic acid **19–21** using EDC and HOBt as condensing agents to afford the desired compounds **22–25** in good yields (Scheme 6).

These derivatives can be considered bifunctional photoprobes (C₆₀ and DNA minor-groove binder). Further developments of this strategy will include water solubilization through conjugation with oligonucleotides or other biologically relevant moieties.³⁴

Conclusions

We have described the synthesis of three amino acids that readily add to C₆₀ in the presence of various aldehydes, leading to amino-functionalized derivatives. To show the versatility and potential uses of these novel

(38) Da Ros, T.; Prato, M.; Novello, F.; Maggini, M.; Banfi, E. J. Org. Chem. 1996, 61, 9070–9072.

intermediates, we have prepared a number of compounds for studies in materials science and medicinal chemistry.

Experimental Section

General. FT-IR spectra were recorded using NaCl cells (oils) or KBr powder (DRIFT system). ^1H and ^{13}C spectra were recorded at 200 and 50 MHz, respectively, in CDCl_3 unless otherwise noted. Chemical shifts are given in parts per million (δ) relative to that of tetramethylsilane. To record ES-MS spectra, the compounds were dissolved in 4/1 THF/methanol unless otherwise noted. Yields in the azomethine ylide cycloadditions are reported as absolute values without taking into account C_{60} recovery (30–40% of the initial fullerene was routinely recovered). C_{60} was purchased from Bucky-USA (99.5%), and all other reagents and solvents were used as purchased from Fluka, Aldrich, J. T. Baker, and Cambridge Isotope Laboratories. The silica gel NM Kieselgel 60 (70–230 mesh ASTM) was obtained from Macherey-Nagel and was used as the support for any column chromatographies. Monoprotected diammines **3a–c**,^{39–41} 12-acetylsulfanilidodecanoic acid,⁴² 4,5,6-trimethoxy-indole-2-carboxylic acid **20**,³³ and benzofuran-2-carboxylic acid **21**⁴³ were prepared according to the literature. All the fullerene derivatives are brown solids.

Synthesis of 4a–c: General Procedure. To a solution of **3a–c** (0.03 mol) in 1,4-dioxane (20 mL) at 0 °C was added a solution of benzyl bromoacetate (2.3 g, 0.01 mol) in 1,4-dioxane (30 mL) over a period of 1 h, and the reaction mixture was stirred overnight. The solvent was evaporated under reduced pressure, and the residue was dissolved in water (70 mL) and extracted with ethyl acetate (3 × 50 mL). The combined organic phase was dried over Na_2SO_4 , and the solvent was removed under vacuum. The crude residue was purified by chromatography (1/1 EtOAc/petroleum ether followed by pure EtOAc) to afford the desired compounds **4** as colorless oils.

4a. $\text{C}_{16}\text{H}_{24}\text{N}_2\text{O}_4$ (MW 308.38), yield: 70% (2.2 g, 7.02 mmol). FT-IR: cm^{-1} 3347, 2974, 2930, 1738, 1694, 1517, 1170, 968, 751. ^1H NMR: δ 7.36 (s, 5H), 5.17 (s, 2H), 4.98 (bs, 1H), 3.45 (s, 2H), 3.19 (m, 2H), 2.74 (t, $J = 5.9$ Hz, 2H), 1.44 (s, 9H). ^{13}C NMR: δ 172.3, 156.0, 135.4, 128.5, 128.3, 128.3, 79.1, 68.0, 66.6, 50.4, 49.7, 28.3. EI-MS: m/z 308 (M^+ , 30%), 253 (8%), 91 (100%).

4b. $\text{C}_{20}\text{H}_{32}\text{N}_2\text{O}_6$ (MW 396.49), yield: 84% (3.3 g, 8.40 mmol). FT-IR: cm^{-1} 3347, 2871, 1712, 1512, 1458, 1368, 1248, 1175, 966, 865, 747, 701. ^1H NMR: δ 7.32 (m, 5H), 5.21 (bs, 1H), 5.15 (s, 2H), 3.59–3.51 (m, 6H), 3.51–3.46 (m, 4H), 3.28 (m, 2H), 2.78 (t, $J = 5.2$ Hz, 2H), 1.41 (s, 9H). ^{13}C NMR: δ 172.1, 155.9, 135.5, 128.5, 128.2, 79.0, 70.6, 70.2, 70.1, 66.5, 50.8, 48.6, 40.4, 40.3, 28.5. EI-MS: m/z 396 (M^+ , 20%), 205 (100%), 161 (40%), 91 (55%).

4c. $\text{C}_{24}\text{H}_{40}\text{N}_2\text{O}_7$ (MW 468.59), yield: 69% (3.2 g, 6.89 mmol). FT-IR: cm^{-1} 3342, 2928, 2868, 1707, 1518, 1458, 1359, 1252, 1174, 976, 866, 746, 702. ^1H NMR: δ 7.33 (s, 5H), 5.13 (s, 2H), 5.06 (bs, 1H), 3.61–3.47 (m, 12H), 3.41 (s, 2H), 3.18 (q, $J = 6.2$ Hz, 2H), 2.66 (t, $J = 6.7$ Hz, 2H), 1.84–1.66 (m, 4H), 1.41 (s, 9H). ^{13}C NMR: δ 172.4, 156.1, 135.6, 128.6, 128.4, 127.0, 79.0, 70.7, 70.3, 69.7, 65.6, 51.1, 47.0, 38.6, 30.1, 29.7, 28.6. EI-MS: m/z 468 (M^+ , 10%), 395 (10%), 367 (5%), 277 (60%), 233 (30%), 178 (100%), 92 (40%), 73 (30%), 59 (40%).

Synthesis of Compounds 1a–c: General Procedure. To a methanol solution (50 mL) of **4** (5.05 mmol) was added 50.0 mg of 10% Pd/C, and the mixture was stirred under a hydrogen atmosphere for 24 h. The catalyst was removed by

filtration on Celite, and the solvent was evaporated. The pure product was triturated in diethyl ether to give a white solid.

1a. Data were in agreement with the literature.³⁹

1b. $\text{C}_{13}\text{H}_{26}\text{N}_2\text{O}_6$ (MW 306.36), yield: 99% (1.6 g, 5.05 mmol). Mp: 105–106 °C. IR-DRIFT: cm^{-1} 3250, 2970, 1706, 1620, 1540, 1365, 1115, 686, 590, 480. ^1H NMR: δ 8.21 (bs, 1H), 6.23 (bs, 1H), 5.54 (bt, 1H), 3.79 (bt, 2H), 3.64–3.53 (m, 8H), 3.49 (t, $J = 5.1$ Hz, 2H), 3.22 (m, 2H), 1.40 (s, 9H). ^{13}C NMR: δ 170.5, 156.2, 79.1, 70.4, 70.3, 70.1, 66.6, 49.8, 46.8, 40.4, 28.6. EI-MS: m/z 306 (M^+). Anal. Calcd for $\text{C}_{13}\text{H}_{26}\text{N}_2\text{O}_6$: C, 50.97; H, 8.55; N, 9.14. Found: C, 51.10; H, 8.65; N, 9.16.

1c. $\text{C}_{17}\text{H}_{34}\text{N}_2\text{O}_7$ (MW 378.49), yield: 99% (1.9 g, 5.05 mmol). Mp: 121–123 °C. IR-DRIFT: cm^{-1} 3338, 3079, 2875, 2230, 1674, 1562, 1382, 1279, 1107, 857. ^1H NMR: δ 5.27 (bs, 1H), 3.73–3.33 (m, 14H), 3.28–2.99 (m, 4H), 2.00 (m, $J = 5.8$ Hz, 2H), 1.71 (m, $J = 6.4$ Hz, 2H), 1.39 (s, 9H). ^{13}C NMR: δ 170.1, 156.1, 78.9, 70.6, 70.5, 70.4, 70.2, 69.5, 69.0, 50.0, 46.1, 38.6, 29.8, 28.6, 26.3. ES-MS (MeOH): m/z 379 (MH^+).

Synthesis of Compounds 8a–f: General Procedure. A toluene solution (300 mL) of C_{60} (500.0 mg, 0.69 mmol) and the appropriate aldehyde (3.45 mmol) and amino acid **1a–c** (1.38 mmol) was heated to reflux for 1 h. After cooling to room temperature, the product was purified by column chromatography. The brown solids were dissolved in CH_2Cl_2 and precipitated by addition of MeOH.

8a. $\text{C}_{69}\text{H}_{18}\text{N}_2\text{O}_2$ (MW 906.93), yield: 42% (264.7 mg, 0.29 mmol). Eluant: 95/5 toluene/AcOEt. IR-DRIFT: cm^{-1} 3355, 2980, 2790, 1705, 1510, 1120, 770, 525, 475. ^1H NMR: δ 5.25 (bs, 1H), 4.45 (s, 4H), 3.67 (m, 2H), 3.24 (t, $J = 5.9$ Hz, 2H), 1.49 (s, 9H). ^{13}C NMR: δ 154.8, 149.1, 147.3, 146.3, 146.1, 146.0, 145.7, 145.5, 145.3, 144.6, 143.1, 142.7, 142.2, 142.1, 141.9, 140.2, 136.3, 70.7, 67.9, 66.0, 54.4, 28.6. UV-vis (cyclohexane): λ_{max} nm 427, 327, 272. ES-MS: m/z 907 (MH^+). Anal. Calcd for $\text{C}_{69}\text{H}_{18}\text{N}_2\text{O}_2$: C, 91.38; H, 2.00; N, 3.09. Found: C, 84.70; H, 2.24; N, 2.74.

8b. $\text{C}_{73}\text{H}_{26}\text{N}_2\text{O}_4$ (MW 995.03), yield: 31% (212.2 mg, 0.21 mmol). Eluant: 9/1 toluene/AcOEt. IR-DRIFT: cm^{-1} 3444, 2921, 2853, 1710, 1498, 1457, 1168, 1121, 794, 545. ^1H NMR: δ 5.08 (bs, 1H), 4.50 (s, 4H), 4.05 (t, $J = 5.5$ Hz, 2H), 3.77 (m, 4H), 3.60 (t, $J = 5.3$ Hz, 2H), 3.36 (m, 4H), 1.44 (s, 9H). ^{13}C NMR: δ 156.0, 155.1, 147.3, 146.3, 146.1, 145.7, 145.4, 145.3, 144.6, 143.1, 142.7, 142.3, 142.1, 141.9, 140.2, 136.2, 79.3, 70.9, 70.7, 70.6, 70.5, 68.6, 54.4, 28.6. UV-vis (cyclohexane): λ_{max} nm 703, 546 (sh), 466 (sh), 429, 309, 254. ES-MS: m/z 995 (MH^+). Anal. Calcd for $\text{C}_{73}\text{H}_{26}\text{N}_2\text{O}_4$: C, 88.12; H, 2.63; N, 2.82. Found: C, 88.20; H, 2.59; N, 2.82.

8c. $\text{C}_{77}\text{H}_{34}\text{N}_2\text{O}_5$ (MW 1067.14), yield: 20% (147.3 mg, 0.14 mmol). Eluant: 95/5 toluene/*i*PrOH. IR-DRIFT: cm^{-1} 3327, 2975, 2874, 2783, 1707, 1505, 1249, 1114, 880, 767. ^1H NMR: δ 5.00 (bs, 1H), 4.40 (s, 4H), 3.82 (t, $J = 6.5$ Hz, 2H), 3.73–3.51 (m, 10H), 3.27–3.14 (m, 4H), 2.21 (m, $J = 6.5$ Hz, 2H), 1.76 (m, $J = 6.3$ Hz, 2H) 1.42 (s, 9H). ^{13}C NMR: δ 156.1, 155.0, 147.3, 146.3, 146.1, 145.7, 145.4, 145.3, 144.6, 143.1, 142.7, 142.3, 142.1, 141.9, 140.2, 136.3, 79.0, 70.8, 70.7, 70.5, 70.4, 69.8, 69.6, 68.0, 51.9, 38.8, 29.8, 29.1, 28.6. UV-vis (THF): λ_{max} nm 705, 431, 327, 255. ES-MS: m/z 1067 (MH^+), 1090 ($\text{M} + \text{Na}^+$). Anal. Calcd for $\text{C}_{77}\text{H}_{34}\text{N}_2\text{O}_5$: C, 86.67; H, 3.21; N, 2.63. Found: C, 82.40; H, 3.24; N, 2.59.

8d. $\text{C}_{83}\text{H}_{34}\text{FeN}_2\text{O}_4$ (MW 1179.05), yield: 31% (252.0 mg, 0.21 mmol). Eluant: 96/4 toluene/AcOEt. IR-DRIFT: cm^{-1} 3440, 3370, 2920, 2862, 1709, 1512, 1250, 1169, 1115, 821, 494. ^1H NMR: δ 5.10 (d, $J = 10.0$ Hz, 1H), 5.02 (s, 1H), 5.00 (bt, 1H), 4.56 (s, 1H), 4.50 (s, 1H), 4.30 (s, 5H), 4.21 (m, 5H), 3.93 (m, 2H), 3.78 (m, 2H), 3.63 (m, 2H), 3.34 (m, 2H), 3.16 (m, 2H), 1.44 (s, 9H). ^{13}C NMR: δ 156.4, 156.0, 154.4, 153.9, 153.4, 147.6, 147.2, 146.5, 146.2, 146.1, 146.1, 145.9, 145.8, 145.6, 145.5, 145.3, 145.2, 144.7, 144.7, 144.4, 143.1, 143.0, 142.7, 142.6, 142.2, 142.1, 141.9, 141.8, 141.6, 141.4, 140.2, 140.1, 139.4, 138.8, 136.5, 136.3, 135.9, 135.7, 87.0, 79.4, 71.1, 71.0, 70.6, 69.5, 68.8, 68.5, 68.3, 67.6, 67.6, 67.3, 53.4, 28.6. UV-vis (toluene): λ_{max} nm 704, 432, 329, 309. ES-MS: m/z 1179 (MH^+). Anal. Calcd for $\text{C}_{83}\text{H}_{34}\text{FeN}_2\text{O}_4$: C, 84.55; H, 2.91; N, 2.38. Found: C, 84.20; H, 3.03; N, 2.37.

8e. $\text{C}_{75}\text{H}_{30}\text{N}_2\text{O}_5$ (MW 1039.09), yield: 17% (121.9 mg, 0.12 mmol). Eluant: 99/1 toluene/*i*PrOH. IR-DRIFT: cm^{-1} 3365,

(39) Muller, D.; Zeltser, I.; Bitan, G.; Gilon, C. *J. Org. Chem.* **1997**, *62*, 411–416.

(40) Beer, P. D.; Cadman, J.; Lloris, J. M.; Martinez-Manez, R.; Soto, J.; Pardo, T.; Marcos, D. *J. Chem. Soc., Dalton Trans.* **2000**, 1805–1812.

(41) Fan, E.; Zhang, Z.; Minke, W. E.; Hou, Z.; Verlinde, C. L. M. J.; Hol, W. G. J. *J. Am. Chem. Soc.* **2000**, *122*, 2663–2664.

(42) Finklea, H. O.; Liu, L.; Ravenscroft, M.; Punturi, S. *J. Phys. Chem.* **1996**, *100*, 18852–18858.

(43) Fuson, R. C.; Kneisley, J. W.; Kaiser, E. W. *Organic Syntheses*; Wiley: New York, 1955; Collect. Vol. III, pp 209–211.

2918, 1710, 1517, 1171, 856, 770, 574, 527. ^1H NMR: δ 5.52 (bs, 1H), 4.88 (d, $J = 9.7$ Hz, 1H), 4.58 (dd, $J = 9.8$ and 3.3 Hz, 1H), 4.44 (m, 1H), 4.38–4.18 (m, 2H), 3.86–3.40 (m, 10H), 3.38 (s, 3H), 3.12 (m, 2H), 1.53 (s, 9H). ^{13}C NMR: δ 156.9, 153.9, 149.5, 148.7, 147.8, 147.3, 147.2, 146.8, 146.4, 146.3, 146.3, 146.2, 146.2, 146.1, 146.0, 145.8, 145.6, 145.5, 145.4, 145.3, 145.2, 144.8, 144.6, 144.4, 143.2, 143.1, 142.7, 142.7, 142.2, 142.0, 141.7, 140.6, 140.3, 140.2, 139.8, 139.5, 135.6, 79.4, 74.5, 74.1, 73.7, 72.5, 72.1, 71.0, 70.7, 70.1, 66.8, 59.2, 28.7. UV-vis (cyclohexane): λ_{max} nm 701, 430, 328, 270, 261. ES-MS: m/z 1039 (MH^+). Anal. Calcd for $\text{C}_{75}\text{H}_{30}\text{N}_2\text{O}_5$: C, 86.69; H, 2.91; N, 2.70. Found: C, 85.00; H, 3.06; N, 2.65.

8f. $\text{C}_{79}\text{H}_{38}\text{N}_2\text{O}_7$ (MW 1127.19), yield: 44% (213.2 mg, 0.19 mmol). Eluant: 98/2 toluene/*i*PrOH. IR-DRIFT: cm^{-1} 3350, 2878, 1710, 1115, 488. ^1H NMR: δ 5.03 (bs, 1H), 4.95 (d, $J = 4.8$ Hz, 1H), 4.55 (m, 1H), 4.37 (m, 2H), 4.25 (d, $J = 4.8$ Hz, 1H), 4.03 (t, $J = 5.5$ Hz, 2H), 3.83–3.68 (m, 8H), 3.64–3.52 (m, 4H), 3.52–3.45 (m, 4H), 3.34 (s, 3H), 3.16 (m, 2H), 1.42 (s, 9H). ^{13}C NMR: δ 155.9, 155.8, 154.6, 153.9, 152.4, 147.1, 147.1, 147.0, 146.2, 146.1, 146.0, 145.9, 145.7, 145.6, 145.5, 145.4, 145.3, 145.2, 145.1, 144.6, 144.5, 144.3, 143.1, 142.9, 142.5, 142.1, 142.0, 141.9, 141.6, 141.5, 140.2, 140.1, 139.6, 139.2, 137.2, 136.3, 135.8, 135.4, 79.2, 74.7, 73.4, 72.1, 71.9, 70.8, 70.5, 70.4, 70.4, 70.2, 70.0, 67.7, 59.2, 59.0, 52.2, 40.4, 28.5. UV-vis (CH_2Cl_2): λ_{max} nm 702, 638 (sh), 470 (sh), 430, 329, 307. ES-MS: m/z 1127 (MH^+), 1165 ($\text{M} + \text{K}^+$). Anal. Calcd for $\text{C}_{79}\text{H}_{38}\text{N}_2\text{O}_7$: C, 84.18; H, 3.40; N, 2.49. Found: C, 84.00; H, 3.53; N, 2.50.

Synthesis of Compounds 9a–e: General Procedure.

A solution of **8** (0.15 mmol) in CH_2Cl_2 (3 mL) and CF_3COOH (3 mL) was stirred at room temperature for 3 h. The solvent and the acid in excess were removed in vacuo. The solid residue was washed with toluene in order to remove any trace of starting material and then dried under vacuum.

9a. $\text{C}_{68}\text{H}_{12}\text{F}_6\text{N}_2\text{O}_4$ (MW 1034.86), yield: 99% (155.2 mg, 0.15 mmol). UV-vis (THF): λ_{max} nm 704, 431, 326, 255. ES-MS: m/z 806 (M^+). Anal. Calcd for $\text{C}_{68}\text{H}_{12}\text{F}_6\text{N}_2\text{O}_4$: C, 78.92; H, 1.17; N, 2.71. Found: C, 76.10; H, 1.17; N, 2.54.

9b. $\text{C}_{72}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_6$ (MW 1122.96), yield: 99% (167.8 mg, 0.15 mmol). IR-DRIFT: cm^{-1} 2890, 1680, 1515, 1480, 1190, 1130, 715, 525. ^1H NMR ($\text{DMSO}-d_6$): δ 7.81 (bs, 3H), 4.58 (s, 4H), 3.93 (t, $J = 5.5$ Hz, 2H), 3.71–3.43 (m, 6H), 3.32 (m, 2H), 2.95 (m, 2H). ^{13}C NMR ($\text{DMSO}-d_6$): δ 156.0, 147.4, 146.7, 146.4, 146.2, 146.0, 145.5, 145.4, 144.7, 143.3, 142.8, 142.5, 142.2, 142.0, 140.2, 136.4, 135.4, 71.5, 70.5, 70.1, 68.0, 67.5, 54.1. UV-vis (cyclohexane): λ_{max} nm 684, 484 (sh), 430, 331. ES-MS: m/z 896 (M^+). Anal. Calcd for $\text{C}_{72}\text{H}_{20}\text{F}_6\text{N}_2\text{O}_6$: C, 77.01; H, 1.80; N, 2.49. Found: C, 77.30; H, 1.56; N, 2.58.

9c. $\text{C}_{76}\text{H}_{28}\text{F}_6\text{N}_2\text{O}_7$ (MW 1195.07), yield: 99% (178.1 mg, 0.15 mmol). IR-DRIFT: cm^{-1} 3732, 2996, 2879, 2771, 1682, 1477, 1429, 1200, 1125, 836, 721, 632. ^1H NMR ($\text{DMSO}-d_6$): δ 7.16 (bs, 3H), 4.43 (s, 4H), 3.70 (t, $J = 6.6$ Hz, 2H), 3.61–3.32 (m, 10H), 3.11 (t, $J = 6.6$ Hz, 2H), 2.83 (m, 2H), 2.08 (m, $J = 6.6$ Hz, 2H), 1.75 (m, $J = 6.8$ Hz, 2H). ^{13}C NMR ($\text{DMSO}-d_6$): δ 156.2, 147.4, 146.8, 146.4, 146.2, 146.0, 145.5, 145.4, 144.8, 143.3, 142.8, 142.5, 142.2, 142.0, 140.2, 136.4, 71.5, 70.6, 70.5, 70.3, 69.3, 68.1, 67.8, 51.6, 37.6, 29.3, 27.9. UV-vis (THF): λ_{max} nm 705, 431, 328, 255. ES-MS: m/z 968 (M^+), 484 (M^{2+}). Anal. Calcd for $\text{C}_{76}\text{H}_{28}\text{F}_6\text{N}_2\text{O}_7$: C, 76.38; H, 2.36; N, 2.34. Found: C, 74.70; H, 2.38; N, 2.44.

9d. $\text{C}_{80}\text{H}_{27}\text{F}_3\text{FeN}_2\text{O}_4$ (MW 1192.96), yield: 90% (161.0 mg, 0.14 mmol). IR-DRIFT: cm^{-1} 3519, 3440, 2775, 1679, 1435, 1188, 1134, 825, 719. ^1H NMR: δ 7.80 (m, 3H), 5.15 (d, $J = 9.5$ Hz, 1H), 5.12 (s, 1H), 4.91 (m, 1H), 4.50 (s, 2H), 4.33 (s, 5H), 4.28 (s, 2H), 4.23 (d, $J = 9.5$ Hz, 1H), 4.11 (bt, 2H), 3.84 (m, 2H), 3.71 (m, 4H), 3.15 (m, 1H), 2.96 (m, 2H). ^{13}C NMR ($\text{DMSO}-d_6$): δ 154.2, 149.7, 147.8, 147.4, 147.1, 146.4, 146.1, 145.6, 145.4, 144.9, 143.2, 142.7, 142.4, 140.2, 136.5, 136.3, 129.6, 128.9, 87.4, 78.1, 70.6, 70.1, 69.4, 68.0, 67.6. UV-vis (THF): λ_{max} nm 703, 430, 325, 304, 255. ES-MS: m/z 1080 (M^+). Anal. Calcd for $\text{C}_{80}\text{H}_{27}\text{F}_3\text{FeN}_2\text{O}_4$: C, 80.55; H, 2.28; N, 2.35. Found: C, 78.00; H, 2.24; N, 2.30.

9e. $\text{C}_{72}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_5$ (MW 1052.99), yield: 99% (156.9 mg, 0.15 mmol). UV-vis (THF): λ_{max} nm 700, 463 (sh), 430, 327, 272,

255. ES-MS: m/z 939 (M^+). Anal. Calcd for $\text{C}_{72}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_5$: C, 82.13; H, 2.20; N, 2.66. Found: C, 80.95; H, 2.19; N, 2.58.

Synthesis of Compounds 10 and 11: General Procedure. To a mixture of **9b** or **9d** (14.9 mmol) in 30 mL of CH_2Cl_2 was added 41 μL (29.8 mmol) of TEA. After the mixture was stirred for 10 min at room temperature, 37.0 mg (14.9 mmol) of 3-(triethoxysilyl)propyl isocyanate was introduced and the whole mixture was left to stir for 16 h at room temperature. After filtration, the solvent was evaporated, and the solid was washed and centrifuged four times with diethyl ether and eventually dried.

10. $\text{C}_{78}\text{H}_{39}\text{N}_3\text{O}_6\text{Si}$ (MW 1142.25), yield: 89% (151.5 mg, 0.13 mmol). IR-DRIFT: cm^{-1} 3359, 2882, 1631, 1567, 1427, 1081, 954, 768. ^1H NMR (400 MHz): δ 4.84 (bt, 1H), 4.70 (bt, 1H), 4.51 (s, 4H), 4.05 (t, $J = 5.0$ Hz, 2H), 3.85–3.72 (m, 10H), 3.61 (t, $J = 5.0$ Hz, 2H), 3.41–3.34 (m, 4H), 3.16 (q, $J = 7.0$ Hz, 2H), 1.66–1.56 (m, 2H), 1.21 (t, $J = 7.0$ Hz, 9H), 0.63 (t, $J = 8.4$ Hz, 2H). ^{13}C NMR: δ 158.4, 154.9, 147.3, 146.3, 146.1, 146.0, 145.7, 145.4, 145.3, 144.6, 143.2, 142.7, 142.2, 142.1, 141.9, 140.2, 136.2, 70.9, 70.4, 68.7, 58.8, 58.6, 43.2, 23.8, 18.5, 7.9. UV-vis (toluene): λ_{max} nm 703, 432, 326. ES-MS: m/z 1142 (MH^+). Anal. Calcd for $\text{C}_{78}\text{H}_{39}\text{N}_3\text{O}_6\text{Si}$: C, 82.02; H, 3.44; N, 3.68. Found: C, 80.40; H, 3.39; N, 3.60.

11. $\text{C}_{88}\text{H}_{47}\text{FeN}_3\text{O}_6\text{Si}$ (MW 1326.30), yield: 93% (153.2 mg, 0.11 mmol). IR-DRIFT: cm^{-1} 3384, 2972, 2915, 1671, 1560, 1458, 1173, 1116, 902, 800, 769. ^1H NMR (400 MHz): δ 5.09 (d, $J = 9.2$ Hz, 1H), 5.03 (s, 1H), 4.67 (bt, 1H), 4.57 (s, 1H), 4.50 (s, 1H), 4.39 (bt, 1H), 4.32 (s, 5H), 4.26 (s, 1H), 4.20 (m, 4H), 3.92 (m, 2H), 3.80 (m, 8H), 3.63 (t, $J = 5.1$ Hz, 2H), 3.39 (m, 2H), 3.17 (m, 2H), 3.10 (q, $J = 6.2$ Hz, 2H), 1.56 (m, 2H), 1.21 (t, $J = 6.9$ Hz, 9H), 0.60 (t, $J = 8.4$ Hz, 2H). ^{13}C NMR: δ 158.1, 156.3, 154.3, 153.8, 153.3, 147.5, 147.3, 146.5, 146.3, 145.9, 145.8, 145.6, 145.4, 145.2, 145.2, 144.7, 144.4, 143.0, 142.7, 142.6, 142.2, 142.1, 141.8, 141.6, 141.4, 140.2, 139.4, 138.8, 136.5, 135.9, 135.7, 97.2, 87.1, 70.9, 79.6, 78.8, 78.4, 77.7, 67.3, 58.6, 23.8, 18.5. UV-vis (toluene): λ_{max} nm 432, 329. ES-MS: m/z 1326 (MH^+). Anal. Calcd for $\text{C}_{88}\text{H}_{47}\text{FeN}_3\text{O}_6\text{Si}$: C, 79.69; H, 3.57; N, 3.17. Found: C, 78.80; H, 3.53; N, 3.15.

Synthesis of Compound 12. A solution containing 12-acetylsulfanilidodecanoic acid (20.9 mg, 0.08 mmol), EDC-HCl (29.3 mg, 0.15 mmol), and HOBT (16.9 mg, 0.15 mmol) was stirred in CH_2Cl_2 (5 mL) at room temperature for 30 min. To this solution was slowly added a mixture of fullerene derivative **9b** (85.3 mg, 0.076 mmol) and NEt_3 (28 μL , 0.23 mmol) in CH_2Cl_2 (5 mL). The resulting reaction mixture was stirred for 12 h at room temperature. The solvent was then evaporated under reduced pressure, and the product was purified by chromatography on silica gel using 9/1 toluene/AcOEt as the eluant.

12. $\text{C}_{82}\text{H}_{42}\text{N}_2\text{O}_4\text{S}$ (MW 1151.32), yield: 53% (46.2 mg, 0.04 mmol). FT-IR: cm^{-1} 3330, 2923, 2851, 1688, 1540, 1460, 1428, 1341, 1184, 1118, 954, 767. ^1H NMR: δ 6.12 (bt, 1H), 4.52 (s, 4H), 4.06 (t, $J = 5.7$ Hz, 2H), 3.83 (m, 2H), 3.74 (m, 2H), 3.61 (m, 2H), 3.48 (m, 2H), 3.39 (m, 2H), 2.83 (t, $J = 7.3$ Hz, 2H), 2.31 (s, 3H), 2.17 (dd, $J = 4.4$ and 8.1 Hz, 2H), 1.56 (m, 4H), 1.24 (m, 14H). ^{13}C NMR: δ 196.1, 173.2, 154.9, 147.3, 146.3, 146.1, 146.0, 145.7, 145.5, 145.3, 144.6, 143.2, 142.7, 142.2, 142.1, 141.9, 140.2, 136.2, 76.5, 70.8, 70.6, 70.4, 70.2, 68.6, 54.5, 39.3, 37.0, 30.8, 29.7, 29.6, 29.6, 29.5, 29.3, 29.3, 29.0, 25.9. UV-vis (toluene): λ_{max} nm 704, 433, 327, 309. ES-MS: m/z 1151 (MH^+). Anal. Calcd for $\text{C}_{82}\text{H}_{42}\text{N}_2\text{O}_4\text{S}$: C, 85.55; H, 3.68; N, 2.43. Found: C, 85.20; H, 3.57; N, 2.45.

Synthesis of Compounds 13–15: General Procedure.

Compound **8b**, **8c**, or **8f** (0.04 mmol) was dissolved in 10 mL of CHCl_3 , and 275 μL (4.40 mmol) of CH_3I was added. The solution was stirred in closed vials for 72 h at 80 °C. The excess of methyl iodide and solvent were removed by evaporation, and the residue was dried under vacuum.

13. $\text{C}_{74}\text{H}_{29}\text{IN}_2\text{O}_4$ (MW 1136.94), yield: 99% (45.5 mg, 0.04 mmol). IR-DRIFT: cm^{-1} 3340, 2970, 1690, 1513, 1112, 767, 521. ^1H NMR ($\text{DMSO}-d_6$): δ 5.75 (m, 4H), 4.45 (m, 2H), 4.24 (m, 2H), 4.15 (s, 3H), 3.74 (m, 2H), 3.61 (m, 2H), 3.44 (m, 2H), 3.01 (m, 2H), 1.30 (s, 9H). UV-vis (CH_2Cl_2): λ_{max} nm 688, 545 (sh), 460 (sh), 428, 317. ES-MS (1/1 $\text{CH}_3\text{CN}/\text{MeOH}$): m/z 1009

(M⁺). Anal. Calcd for C₇₄H₂₉IN₂O₄: C, 78.17; H, 2.57; N, 2.46. Found: C, 73.40; H, 2.44; N, 2.38.

14. C₈₀H₄₁IN₂O₇ (MW 1269.13), yield: 99% (50.7 mg, 0.04 mmol). IR-DRIFT: cm⁻¹ 2875, 1703, 1460, 1110, 520. ¹H NMR (two diastereoisomers in a 70/30 ratio): major isomer, δ 6.56 (d, *J* = 12.5 Hz, 1H), 5.78 (d, *J* = 12.2 Hz, 1H), 5.37 (m, 1H), 5.07–4.73 (m, 4H), 4.60–4.31 (m, 2H), 4.34 (s, 3H), 4.04–3.84 (m, 4H), 3.78–3.64 (m, 6H), 3.59–3.51 (m, 4H), 3.38 (s, 3H), 3.25 (m, 2H), 1.40 (s, 9H); minor isomer, diagnostic peaks, δ 6.65 (d, *J* = 6.2 Hz, 1H), 6.11 (d, *J* = 6.2 Hz, 1H), 4.51 (s, 3H). ¹³C NMR: δ 155.7, 151.9, 149.5, 148.9, 148.8, 147.4, 147.3, 146.4, 146.3, 146.3, 146.1, 146.1, 145.8, 145.8, 145.7, 145.5, 145.4, 145.1, 144.7, 144.6, 144.6, 144.5, 144.5, 144.4, 144.4, 144.2, 144.1, 143.1, 143.0, 142.8, 142.8, 142.7, 142.1, 142.1, 142.0, 141.7, 141.6, 141.0, 140.8, 140.5, 140.1, 140.0, 139.9, 137.7, 136.8, 136.3, 135.8, 79.4, 72.1, 71.8, 71.1, 70.9, 70.7, 70.4, 70.4, 70.1, 68.1, 68.0, 67.8, 66.2, 65.8, 59.1, 45.6, 40.3, 28.5. UV-vis (CH₂Cl₂): λ_{max} nm 686, 605 (sh), 462 (sh), 426, 317. ES-MS (MeOH): *m/z* 1142 (M⁺). Anal. Calcd for C₈₀H₄₁IN₂O₇: C, 75.71; H, 3.26; N, 2.21. Found: C, 73.60; H, 3.12; N, 2.25.

15. C₇₈H₃₇IN₂O₅ (MW 1209.08), yield: 96% (46.4 mg, 0.04 mmol). IR-DRIFT: cm⁻¹ 3515, 2974, 2878, 1695, 1505, 1363, 1249, 1114, 861, 768, 652. ¹H NMR (DMSO-*d*₆): δ 5.76 (m, 4H), 4.42–4.29 (m, 2H), 4.08 (s, 3H), 3.71 (t, *J* = 5.2 Hz, 2H), 3.64–3.24 (m, 10H), 2.98–2.86 (m, 2H), 2.45–2.37 (m, 2H), 1.56 (m, *J* = 6.6 Hz, 2H), 1.33 (s, 3H). ¹³C NMR (DMSO-*d*₆): δ 153.1, 152.5, 147.6, 146.6, 146.6, 146.3, 146.3, 145.9, 145.8, 145.7, 145.6, 145.5, 144.7, 144.6, 143.4, 143.3, 143.0, 142.9, 142.3, 142.2, 142.2, 141.7, 141.7, 140.1, 140.1, 136.71, 136.5, 78.2, 72.3, 70.6, 70.5, 70.3, 69.3, 68.9, 68.0, 63.8, 49.0, 38.1, 30.5, 29.1, 24.7. UV-vis (CH₂Cl₂): λ_{max} nm 688, 427, 316, 253. ES-MS: *m/z* 1081 (M⁺). Anal. Calcd for C₇₈H₃₇IN₂O₅: C, 77.49; H, 3.08; N, 2.32. Found: C, 75.80; H, 3.09; N, 2.27.

Synthesis of Compounds 16–18: General Procedure. HCl gas was bubbled for 15 min through a methanol solution (15 mL) of **13**, **14**, or **15** (0.02 mmol) after which the solvent was removed in vacuo. The remaining solids were washed with toluene and dried under vacuum.

16. C₆₉H₂₂ClIN₂O₂ (MW 1073.31), yield: 99% (21.4 mg, 0.02 mmol). IR-DRIFT: cm⁻¹ 3344, 2969, 1633, 1434, 1110, 520. ¹H NMR (DMSO-*d*₆): δ 8.02 (bs, 3H), 5.25 (bs, 4H), 4.16 (m, 2H), 3.90–3.63 (m, 11H), 2.93 (m, 2H). UV-vis (H₂O): λ_{max} nm 702, 428, 338, 262, 204. ES-MS (H₂O): *m/z* 910 (M⁺), 455 (M²⁺). Anal. Calcd for C₆₉H₂₂ClIN₂O₂: C, 77.20; H, 2.07; N, 2.61. Found: C, 77.40; H, 2.40; N, 2.58.

17. C₇₅H₃₄ClIN₂O₅ (MW 1205.44), yield: 99% (24.1 mg, 0.02 mmol). IR-DRIFT: cm⁻¹ 3348, 2875, 1450, 1115, 525. ¹H NMR (DMSO-*d*₆): δ 8.12 (bs, 3H), 6.35–5.65 (series of multiplets, 3H), 4.96–4.45 (series of multiplets, 4H), 4.28–3.93 (series of multiplets, 6H), 3.84–3.26 (series of multiplets, 13H), 3.20 (s, 3H), 2.92 (m, 2H). UV-vis (H₂O): λ_{max} nm 703, 330, 258, 204. ES-MS (H₂O): *m/z* 1042 (M⁺), 521 (M²⁺). Anal. Calcd for C₇₅H₃₄ClIN₂O₅: C, 74.73; H, 2.84; N, 2.32. Found: C, 72.60; H, 2.35; N, 2.07.

18. C₇₃H₃₀ClIN₂O₃ (MW 1145.42), yield: 99% (22.9 mg, 0.02 mmol). IR-DRIFT: cm⁻¹ 3515, 2988, 2882, 2756, 2035, 1713, 1486, 1109, 947, 768. ¹H NMR (DMSO-*d*₆): δ 7.99 (bs, 3H), 5.08 (m, 4H), 4.47–4.33 (m, 2H), 4.10 (s, 3H), 3.71 (t, *J* = 5.2 Hz, 2H), 3.65–3.24 (m, 10H), 2.86–2.71 (m, 2H), 2.45–2.36 (m, 2H), 1.77 (m, *J* = 6.6 Hz, 2H). ¹³C NMR (DMSO-*d*₆): δ 153.2, 152.5, 147.5, 146.6, 146.5, 146.3, 146.3, 145.9, 145.9, 145.8, 145.8, 145.7, 145.6, 145.5, 144.7, 144.6, 143.4, 143.4, 143.0, 142.9, 142.7, 142.2, 142.2, 141.7, 141.7, 140.1, 140.0, 136.8, 136.6, 72.2, 70.6, 70.4, 70.2, 69.3, 68.1, 63.4, 48.9, 37.3, 27.9, 24.8. UV-vis (CH₂Cl₂): λ_{max} nm 689, 428, 317, 255. ES-MS: *m/z* 982 (M⁺), 491 (M²⁺). Anal. Calcd for C₇₃H₃₀ClIN₂O₃: C, 76.55; H, 2.64; N, 2.45. Found: C, 73.20; H, 2.73; N, 2.52.

Synthesis of Compounds 22–25: General Procedure. A solution of HOBt (20.7 mg, 0.15 mmol), EDC·HCl (29.3 mg, 0.15 mmol), and acid **19**, **20**, or **21** (0.11 mmol) in CH₂Cl₂ (10 mL) was stirred for 15 min and then added dropwise to a suspension of ammonium salt **9a** or **9e** (0.08 mmol) in CH₂Cl₂ (30 mL) and 4-methyl morpholine (17 μL, 0.15 mmol) at 0 °C. After 20 min, the mixture was washed with water and

separated, and the combined organic fractions were dried over Na₂SO₄ and concentrated under reduced pressure. The crude product was purified by flash chromatography. The brown solid compounds were dissolved in CH₂Cl₂ and precipitated by addition of methanol.

22. C₇₆H₂₁N₃O₄ (MW 1040.03), yield: 51% (40.3 mg, 0.04 mmol). Eluant: 9/1 toluene/AcOEt. IR-DRIFT: cm⁻¹ 3325, 2824, 1646, 1119, 527. ¹H NMR (3/1 CDCl₃/CS₂): δ 9.30 (bs, 1H), 7.12 (bs, 1H), 6.84 (s, 1H), 6.66 (s, 1H), 4.53 (s, 4H), 4.04 (s, 3H), 4.01 (m, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.44 (t, *J* = 6.1 Hz, 2H). ¹³C NMR (3/1 CDCl₃/CS₂): δ 161.4, 154.4, 150.1, 147.3, 146.3, 146.1, 145.9, 145.5, 145.3, 144.6, 143.2, 142.7, 142.2, 142.1, 141.9, 140.3, 136.1, 130.6, 125.9, 123.4, 70.6, 67.4, 61.3, 61.0, 56.2, 53.0. UV-vis (cyclohexane): λ_{max} nm 700, 636 (sh), 430, 402 (sh), 328, 273, 255. ES-MS: *m/z* 1040 (MH⁺). Anal. Calcd for C₇₆H₂₁N₃O₄: C, 87.77; H, 2.04; N, 4.04. Found: C, 82.70; H, 2.02; N, 3.77.

23. C₈₂H₃₃N₃O₇ (MW 1172.19), yield: 78% (69.0 mg, 0.06 mmol). Eluant: 99/1 toluene/iPrOH. IR-DRIFT: cm⁻¹ 3274, 2933, 1649, 1120, 760, 530. ¹H NMR: δ 9.31 (bs, 1H), 7.56 (bs, 1H), 7.01 (s, 1H), 6.74 (s, 1H), 4.92 (d, *J* = 10.0 Hz, 1H), 4.65 (d, *J* = 10.0 Hz, 1H), 4.53 (m, 1H), 4.37 (m, 2H), 4.05 (s, 3H), 3.97–3.34 (m, 12H), 3.89 (s, 3H), 3.83 (s, 3H), 3.34 (s, 3H). ¹³C NMR: δ 161.8, 155.6, 154.3, 153.4, 152.7, 149.9, 147.3, 147.2, 146.6, 146.3, 146.3, 146.2, 146.2, 146.1, 146.1, 146.0, 145.7, 145.6, 145.5, 145.4, 145.3, 145.3, 145.2, 145.2, 144.7, 144.5, 144.4, 144.4, 143.1, 143.1, 142.7, 142.7, 142.6, 142.2, 142.2, 142.1, 142.0, 141.8, 141.7, 140.3, 140.2, 140.0, 139.8, 139.6, 139.1, 136.9, 136.1, 136.1, 135.7, 131.1, 125.8, 123.4, 74.0, 73.6, 72.0, 70.8, 70.6, 70.5, 69.9, 61.6, 61.2, 59.1, 56.4, 50.1, 37.9, 29.8. UV-vis (cyclohexane): λ_{max} nm 255, 328, 402 (sh), 430, 458 (sh), 550 (sh), 636 (sh), 701. ES-MS: *m/z* 1172 (MH⁺). Anal. Calcd for C₈₂H₃₃N₃O₇: C, 84.02; H, 2.84; N, 3.58. Found: C, 79.80; H, 2.89; N, 3.33.

24. C₇₉H₂₇N₃O₄ (MW 1082.11), yield: 60% (51.8 mg, 0.05 mmol). Eluant: 99/1 toluene/iPrOH. IR-DRIFT: cm⁻¹ 3265, 2880, 1640, 1115, 527. ¹H NMR: δ 9.46 (bs, 1H), 7.70 (bt, 1H), 7.54 (d, *J* = 7.0 Hz, 1H), 7.39 (d, *J* = 8.4 Hz, 1H), 7.20 (t, *J* = 8.4 Hz, 1H), 7.04 (t, *J* = 7.0 Hz, 2H), 4.89 (d, *J* = 9.9 Hz, 1H), 4.65 (dd, *J* = 10.2 and 2.9 Hz, 1H), 4.54 (dd, *J* = 8.9 and 2.9 Hz, 1H), 4.38 (m, 1H), 4.34 (d, *J* = 9.5 Hz, 1H), 4.18–3.38 (m, 12H), 3.38 (s, 3H). ¹³C NMR: δ 161.9, 155.6, 154.3, 152.7, 146.6, 146.2, 146.0, 145.6, 145.3, 143.2, 143.1, 142.7, 142.2, 142.2, 142.1, 141.8, 140.4, 140.0, 139.6, 136.9, 136.3, 136.1, 135.7, 131.3, 127.8, 124.4, 122.0, 120.6, 112.0, 74.8, 74.1, 73.5, 72.0, 70.9, 70.5, 69.9, 66.1, 66.0, 59.1, 50.1, 37.9. UV-vis (cyclohexane): λ_{max} nm 702, 540 (sh), 430, 405 (sh), 329, 302 (sh), 274, 253. ES-MS: 1082 (MH⁺). Anal. Calcd for C₇₉H₂₇N₃O₄: C, 87.69; H, 2.52; N, 3.88. Found: C, 85.90; H, 2.58; N, 3.78.

25. C₇₃H₁₄N₂O₂ (MW 950.94), yield: 88% (66.9 mg, 0.07 mmol). Eluant: 99/1 toluene/iPrOH. IR-DRIFT: cm⁻¹ 2920, 2805, 1671, 1595, 1504, 1341, 1178, 747. ¹H NMR (3/1 CDCl₃/CS₂): δ 7.79 (bt, 1H), 7.66 (m, 1H), 7.53 (m, 2H) 7.38 (m, 1H), 7.27 (m, 1H), 4.55 (s, 4H), 4.03 (m, 2H), 3.45 (t, *J* = 6.0 Hz, 2H). ¹³C NMR (3/1 CDCl₃/CS₂): δ 158.7, 154.5, 154.4, 148.7, 147.2, 146.1, 145.9, 145.8, 145.4, 145.1, 144.4, 143.0, 142.5, 142.0, 141.9, 141.7, 140.1, 136.1, 127.5, 126.9, 123.6, 122.7, 111.7, 110.4, 70.5, 67.1, 52.3, 37.5. UV-vis (cyclohexane): λ_{max} nm 702, 465 (sh), 432, 328, 305, 255, 209. ES-MS: *m/z* 951 (MH⁺). Anal. Calcd for C₇₃H₁₄N₂O₂: C, 92.21; H, 1.48; N, 2.95. Found: C, 88.90; H, 1.76; N, 2.69.

Acknowledgment. This work was supported by MURST (PRIN Prot MM03198284), by CNR through the program “Materiali Innovativi” (legge 95/95), by Regione Friuli-Venezia Giulia (Fondo 1998), and by the European Union (DGXII).

Supporting Information Available: ¹H and ¹³C or ES-MS spectra for compounds **8a**, **8c**, **9a**, **9c**, **10**, **13–15**, **17**, **18**, and **22–25**. This material is available free of charge via the Internet at <http://pubs.acs.org>.